{"url_path":"/sec/eltx/8-k/2026-06-17/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 Other Events.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-17","source_url":"https://www.sec.gov/Archives/edgar/data/1601485/0001601485-26-000048-index.html","accession_number":"0001601485-26-000048","cik":"0001601485","ticker":"ELTX","issuer_name":"Elicio Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1601485/0001601485-26-000048-index.html","primary_entity_key":"0001601485","primary_entity_name":"Elicio Therapeutics, Inc."},"word_count":82,"has_tables":true,"body_markdown":"Item 8.01 Other Events.\n\nOn June 17, 2026, Elicio Therapeutics, Inc. (the “Company”) issued a press release announcing preliminary clinical observations which the Company believes support the evaluation of ELI-002 7P in combination with checkpoint inhibition as well as the Company’s plans to conduct a Phase 1 study in first-line metastatic mutant KRAS pancreatic ductal adenocarcinoma, subject to funding. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference."}